Fintel · Aug 28, 2026
AC
NYSE · ACH
Accendra Health, Inc.
Healthcare · Medical - Distribution
$1.07
Down-$0.04 (-3.60%)
Updated Sep 17, 2026, 1:17 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 187.18M
- P/E ratio
- -0.17
- Dividend yield
- 0.00%
- 52-week range
- $0.93 – $4.69
- Volume
- 1.24M
- Avg. volume
- 1.59M
Price performance
ACH price history
1M range · 20 trading sessions · Daily adjusted prices
ACH closed at $1.07 after 20 trading sessions, down 18.94% for the selected period.
- Last close
- $1.07
- Period change
- -18.94%
- Period low
- $1.07
- Period high
- $1.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.10 | $1.11 | $1.04 | $1.07 | 1.24M |
| Sep 15, 2026 | $1.13 | $1.13 | $1.055 | $1.11 | 675.74K |
| Sep 14, 2026 | $1.04 | $1.145 | $1.03 | $1.12 | 872.66K |
| Sep 11, 2026 | $1.11 | $1.11 | $1.05 | $1.08 | 1.03M |
| Sep 10, 2026 | $1.05 | $1.095 | $0.9601 | $1.08 | 1.09M |
| Sep 9, 2026 | $1.11 | $1.15 | $1.06 | $1.07 | 796.04K |
| Sep 8, 2026 | $1.24 | $1.24 | $1.08 | $1.10 | 810.84K |
| Sep 4, 2026 | $1.21 | $1.22 | $1.19 | $1.21 | 339.17K |
| Sep 3, 2026 | $1.19 | $1.26 | $1.18 | $1.22 | 944.06K |
| Sep 2, 2026 | $1.14 | $1.22 | $1.13 | $1.17 | 898.29K |
| Sep 1, 2026 | $1.18 | $1.20 | $1.12 | $1.15 | 1.07M |
| Aug 31, 2026 | $1.20 | $1.24 | $1.155 | $1.21 | 1.01M |
| Aug 28, 2026 | $1.22 | $1.25 | $1.195 | $1.21 | 678.5K |
| Aug 27, 2026 | $1.23 | $1.23 | $1.17 | $1.21 | 814.18K |
| Aug 26, 2026 | $1.18 | $1.23 | $1.135 | $1.22 | 776.3K |
| Aug 25, 2026 | $1.14 | $1.18 | $1.09 | $1.16 | 1.11M |
| Aug 24, 2026 | $1.17 | $1.19 | $1.10 | $1.16 | 1.44M |
| Aug 21, 2026 | $1.28 | $1.31 | $1.175 | $1.20 | 1.69M |
| Aug 20, 2026 | $1.29 | $1.37 | $1.235 | $1.31 | 2.49M |
| Aug 19, 2026 | $1.12 | $1.32 | $1.10 | $1.32 | 3.87M |
Latest ACH news
The latest Smart Investors Daily articles mentioning ACH.
Stock researchCompany · Overview
ACH research
Overview
Company profile and research snapshot.
Company profile
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $12.39
- Implied upside
- —
- Analysts
- 2
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | UBS | Neutral | — |
| Aug 11, 2026 | Citigroup | Neutral | — |
| Jul 24, 2026 | Citigroup | Buy | — |
| May 12, 2026 | Baird | Outperform | — |
| May 12, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Accendra Health Updates Capital Plans; Nets $45M From Non-Core Asset Sales And Sets CEO Succession Timeline For September
Accendra Health (the "Company") is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.Given recent market conditions, the Company has
Benzinga · Aug 13, 2026
UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.
Fintel · Aug 12, 2026
Citigroup Downgrades Accendra Health (ACH)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
